Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
BMC Cancer
Published in: BMC Cancer 1/2011

Open Access 01-12-2011 | Research article

Bim and Mcl-1 exert key roles in regulating JAK2V617Fcell survival

Authors: Joëlle Rubert, Zhiyan Qian, Rita Andraos, Daniel A Guthy, Thomas Radimerski

Published in: BMC Cancer | Issue 1/2011

Login to get access

Abstract

Background

The JAK2V617F mutation plays a major role in the pathogenesis of myeloproliferative neoplasms and is found in the vast majority of patients suffering from polycythemia vera and in roughly every second patient suffering from essential thrombocythemia or from primary myelofibrosis. The V617F mutation is thought to provide hematopoietic stem cells and myeloid progenitors with a survival and proliferation advantage. It has previously been shown that activated JAK2 promotes cell survival by upregulating the anti-apoptotic STAT5 target gene Bcl-xL. In this study, we have investigated the role of additional apoptotic players, the pro-apoptotic protein Bim as well as the anti-apoptotic protein Mcl-1.

Methods

Pharmacological inhibition of JAK2/STAT5 signaling in JAK2V617F mutant SET-2 and MB-02 cells was used to study effects on signaling, cell proliferation and apoptosis by Western blot analysis, WST-1 proliferation assays and flow cytometry. Cells were transfected with siRNA oligos to deplete candidate pro- and anti-apoptotic proteins. Co-immunoprecipitation assays were performed to assess the impact of JAK2 inhibition on complexes of pro- and anti-apoptotic proteins.

Results

Treatment of JAK2V617F mutant cell lines with a JAK2 inhibitor was found to trigger Bim activation. Furthermore, Bim depletion by RNAi suppressed JAK2 inhibitor-induced cell death. Bim activation following JAK2 inhibition led to enhanced sequestration of Mcl-1, besides Bcl-xL. Importantly, Mcl-1 depletion by RNAi was sufficient to compromise JAK2V617F mutant cell viability and sensitized the cells to JAK2 inhibition.

Conclusions

We conclude that Bim and Mcl-1 have key opposing roles in regulating JAK2V617F cell survival and propose that inactivation of aberrant JAK2 signaling leads to changes in Bim complexes that trigger cell death. Thus, further preclinical evaluation of combinations of JAK2 inhibitors with Bcl-2 family antagonists that also tackle Mcl-1, besides Bcl-xL, is warranted to assess the therapeutic potential for the treatment of chronic myeloproliferative neoplasms.
Appendix
Available only for authorised users
Literature
1.
Nelson ME, Steensma DP: JAK2 V617F in myeloid disorders: What do we know now, and where are we headed?. Leuk Lymphoma. 2006, 47: 177-194. 10.1080/10428190500301348.CrossRefPubMed
2.
Saharinen P, Vihinen M, Silvennoinen O: Autoinhibition of Jak2 Tyrosine Kinase Is Dependent on Specific Regions in Its Pseudokinase Domain. Mol Biol Cell. 2003, 14: 1448-1459. 10.1091/mbc.E02-06-0342.CrossRefPubMedPubMedCentral
3.
Levine RL, Wadleigh M, Cools J, Ebert BL, Wernig G, Huntly BJP, Boggon TJ, Wlodarska I, Clark JJ, Moore S, et al: Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. Cancer Cell. 2005, 7: 387-397. 10.1016/j.ccr.2005.03.023.CrossRefPubMed
4.
Vannucchi AM: How do JAK2-inhibitors work in myelofibrosis: An alternative hypothesis. Leukemia Res. 2009, 33: 1581-1583. 10.1016/j.leukres.2009.06.001.CrossRef
5.
Mesa R, Gale RP: Hypothesis: How do JAK2-inhibitors work in myelofibrosis. Leukemia Res. 2009, 33: 1156-1157. 10.1016/j.leukres.2009.04.011.CrossRef
6.
Jamieson CH, Gotlib J, Durocher JA, Chao MP, Mariappan MR, Lay M, Jones C, Zehnder JL, Lilleberg SL, Weissman IL: The JAK2 V617F mutation occurs in hematopoietic stem cells in polycythemia vera and predisposes toward erythroid differentiation. Proc Natl Acad Sci USA. 2006, 103: 6224-6229. 10.1073/pnas.0601462103.CrossRefPubMedPubMedCentral
7.
Laubach JP, Fu P, Jiang X, Salter KH, Potti A, Arcasoy MO: Polycythemia vera erythroid precursors exhibit increased proliferation and apoptosis resistance associated with abnormal RAS and PI3K pathway activation. Exp Hematol. 2009, 37: 1411-1422. 10.1016/j.exphem.2009.09.009.CrossRefPubMedPubMedCentral
8.
Silva M, Richard C, Benito A, Sanz C, Olalla I, Fernandez-Luna JL: Expression of Bcl-x in Erythroid Precursors from Patients with Polycythemia Vera. N Engl J Med. 1998, 338: 564-571. 10.1056/NEJM199802263380902.CrossRefPubMed
9.
Zeuner A, Pedini F, Francescangeli F, Signore M, Girelli G, Tafuri A, De Maria R: Activity of the BH3 mimetic ABT-737 on polycythemia vera erythroid precursor cells. Blood. 2009, 113: 1522-1525. 10.1182/blood-2008-03-143321.CrossRefPubMed
10.
Gozgit JM, Bebernitz G, Patil P, Ye M, Parmentier J, Wu J, Su N, Wang T, Ioannidis S, Davies A, et al: Effects of the JAK2 Inhibitor, AZ960, on Pim/BAD/BCL-xL Survival Signaling in the Human JAK2 V617F Cell Line SET-2. J Biol Chem. 2008, 283: 32334-32343. 10.1074/jbc.M803813200.CrossRefPubMed
11.
12.
Zhang B, Gojo I, Fenton RG: Myeloid cell factor-1 is a critical survival factor for multiple myeloma. Blood. 2002, 99: 1885-1893. 10.1182/blood.V99.6.1885.CrossRefPubMed
13.
Kaufmann SH, Karp JE, Svingen PA, Krajewski S, Burke PJ, Gore SD, Reed JC: Elevated Expression of the Apoptotic Regulator Mcl-1 at the Time of Leukemic Relapse. Blood. 1998, 91: 991-1000.PubMed
14.
Pissot-Soldermann C, Gerspacher M, Furet P, Gaul C, Holzer P, McCarthy C, Radimerski T, Regnier CH, Baffert F, Drueckes P, et al: Discovery and SAR of potent, orally available 2,8-diaryl-quinoxalines as a new class of JAK2 inhibitors. Bioorg Med Chem Lett. 2010, 20: 2609-2613. 10.1016/j.bmcl.2010.02.056.CrossRefPubMed
15.
Gomez-Bougie P, Bataille R, Amiot M: The imbalance between Bim and Mcl-1 expression controls the survival of human myeloma cells. Eur J Immunol. 2004, 34: 3156-3164. 10.1002/eji.200424981.CrossRefPubMed
16.
Ewings KE, Hadfield-Moorhouse K, Wiggins CM, Wickenden JA, Balmanno K, Gilley R, Degenhardt K, White E, Cook SJ: ERK1/2-dependent phosphorylation of BimEL promotes its rapid dissociation from Mcl-1 and Bcl-xL. EMBO J. 2007, 26: 2856-2867. 10.1038/sj.emboj.7601723.CrossRefPubMedPubMedCentral
17.
Baffert F, Régnier CH, De Pover A, Pissot-Soldermann C, Tavares GA, Blasco F, Brueggen J, Chène P, Drueckes P, Erdmann D, et al: Potent and Selective Inhibition of Polycythemia by the Quinoxaline JAK2 Inhibitor NVP-BSK805. Mol Cancer Ther. 2010, 9: 1945-1955. 10.1158/1535-7163.MCT-10-0053.CrossRefPubMed
18.
Uozumi K, Otsuka M, Ohno N, Moriyama T, Suzuki S, Shimotakahara S, Matsumura I, Hanada S, Arima T: Establishment and characterization of a new human megakaryoblastic cell line (SET-2) that spontaneously matures to megakaryocytes and produces platelet-like particles. Leukemia. 2000, 14: 142-152. 10.1038/sj.leu.2401608.CrossRefPubMed
19.
Morgan DA, Gumucio DL, Brodsky I: Granulocyte-macrophage colony-stimulating factor-dependent growth and erythropoietin-induced differentiation of a human cell line MB-02. Blood. 1991, 78: 2860-2871.PubMed
20.
Adams JM: Ways of dying: multiple pathways to apoptosis. Genes Dev. 2003, 17: 2481-2495. 10.1101/gad.1126903.CrossRefPubMed
21.
Will B, Siddiqi T, Jorda MA, Shimamura T, Luptakova K, Staber PB, Costa DB, Steidl U, Tenen DG, Kobayashi S: Apoptosis induced by JAK2 inhibition is mediated by Bim and enhanced by the BH3 mimetic ABT-737 in JAK2 mutant human erythroid cells. Blood. 2010, 115: 2901-2909. 10.1182/blood-2009-03-209544.CrossRefPubMedPubMedCentral
22.
Chao J-R, Wang J-M, Lee S-F, Peng H-W, Lin Y-H, Chou C-H, Li J-C, Huang H-M, Chou C-K, Kuo M-L, et al: mcl-1 Is an Immediate-Early Gene Activated by the Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF) Signaling Pathway and Is One Component of the GM-CSF Viability Response. Mol Cell Biol. 1998, 18: 4883-4898.CrossRefPubMedPubMedCentral
23.
Maurer U, Charvet C, Wagman AS, Dejardin E, Green DR: Glycogen Synthase Kinase-3 Regulates Mitochondrial Outer Membrane Permeabilization and Apoptosis by Destabilization of MCL-1. Mol Cell. 2006, 21: 749-760. 10.1016/j.molcel.2006.02.009.CrossRefPubMed
24.
Zhong Q, Gao W, Du F, Wang X: Mule/ARF-BP1, a BH3-Only E3 Ubiquitin Ligase, Catalyzes the Polyubiquitination of Mcl-1 and Regulates Apoptosis. Cell. 2005, 121: 1085-1095. 10.1016/j.cell.2005.06.009.CrossRefPubMed
25.
Moulding DA, Quayle JA, Hart CA, Edwards SW: Mcl-1 Expression in Human Neutrophils: Regulation by Cytokines and Correlation With Cell Survival. Blood. 1998, 92: 2495-2502.PubMed
26.
Harada H, Quearry B, Ruiz-Vela A, Korsmeyer SJ: Survival factor-induced extracellular signal-regulated kinase phosphorylates BIM, inhibiting its association with BAX and proapoptotic activity. Proc Natl Acad Sci USA. 2004, 101: 15313-15317. 10.1073/pnas.0406837101.CrossRefPubMedPubMedCentral
27.
Garcon L, Rivat C, James C, Lacout C, Camara-Clayette V, Ugo V, Lecluse Y, Bennaceur-Griscelli A, Vainchenker W: Constitutive activation of STAT5 and Bcl-xL overexpression can induce endogenous erythroid colony formation in human primary cells. Blood. 2006, 108: 1551-1554. 10.1182/blood-2005-10-009514.CrossRefPubMed
28.
Zhao R, Follows GA, Beer PA, Scott LM, Huntly BJP, Green AR, Alexander DR: Inhibition of the Bcl-xL Deamidation Pathway in Myeloproliferative Disorders. N Engl J Med. 2008, 359: 2778-2789. 10.1056/NEJMoa0804953.CrossRefPubMed
29.
Willis SN, Chen L, Dewson G, Wei A, Naik E, Fletcher JI, Adams JM, Huang DCS: Proapoptotic Bak is sequestered by Mcl-1 and Bcl-xL, but not Bcl-2, until displaced by BH3-only proteins. Genes Dev. 2005, 19: 1294-1305. 10.1101/gad.1304105.CrossRefPubMedPubMedCentral
30.
Luciano F, Jacquel A, Colosetti P, Herrant M, Cagnol S, Pages G, Auberger P: Phosphorylation of Bim-EL by Erk1//2 on serine 69 promotes its degradation via the proteasome pathway and regulates its proapoptotic function. Oncogene. 2003, 22: 6785-6793. 10.1038/sj.onc.1206792.CrossRefPubMed
31.
Wiggins CM, Band H, Cook SJ: c-Cbl is not required for ERK1/2-dependent degradation of BimEL. Cell Signal. 2007, 19: 2605-2611. 10.1016/j.cellsig.2007.08.008.CrossRefPubMedPubMedCentral
32.
Nguyen M, Marcellus RC, Roulston A, Watson M, Serfass L, Murthy Madiraju SR, Goulet D, Viallet J, Bélec L, Billot X, et al: Small molecule obatoclax (GX15-070) antagonizes MCL-1 and overcomes MCL-1-mediated resistance to apoptosis. Proc Natl Acad Sci USA. 2007, 104: 19512-19517. 10.1073/pnas.0709443104.CrossRefPubMedPubMedCentral
33.
Tse C, Shoemaker AR, Adickes J, Anderson MG, Chen J, Jin S, Johnson EF, Marsh KC, Mitten MJ, Nimmer P, et al: ABT-263: A Potent and Orally Bioavailable Bcl-2 Family Inhibitor. Cancer Res. 2008, 68: 3421-3428. 10.1158/0008-5472.CAN-07-5836.CrossRefPubMed
34.
Bouillet P, Metcalf D, Huang DC, Tarlinton DM, Kay TW, Köntgen F, Adams JM, Strasser A: Proapoptotic Bcl-2 Relative Bim Required for Certain Apoptotic Responses, Leukocyte Homeostasis, and to Preclude Autoimmunity. Science. 1999, 286: 1735-1738. 10.1126/science.286.5445.1735.CrossRefPubMed
35.
Abutin RM, Chen J, Lung TK, Lloyd JA, Sawyer ST, Harada H: Erythropoietin-induced phosphorylation/degradation of BIM contributes to survival of erythroid cells. Exp Hematol. 2009, 37: 151-158. 10.1016/j.exphem.2008.10.008.CrossRefPubMed
36.
Dijkers PF, Medema RH, Lammers J-W, Koenderman L, Coffer PJ: Expression of the pro-apoptotic Bcl-2 family member Bim is regulated by the forkhead transcription factor FKHR-L1. Curr Biol. 2000, 10: 1201-1204. 10.1016/S0960-9822(00)00728-4.CrossRefPubMed
37.
Essafi A, Fernandez de Mattos S, Hassen YAM, Soeiro I, Mufti GJ, Thomas NSB, Medema RH, Lam EWF: Direct transcriptional regulation of Bim by FoxO3a mediates STI571-induced apoptosis in Bcr-Abl-expressing cells. Oncogene. 2005, 24: 2317-2329. 10.1038/sj.onc.1208421.CrossRefPubMed
38.
Maeda T, Ito K, Merghoub T, Poliseno L, Hobbs RM, Wang G, Dong L, Maeda M, Dore LC, Zelent A, et al: LRF Is an Essential Downstream Target of GATA1 in Erythroid Development and Regulates BIM-Dependent Apoptosis. Dev Cell. 2009, 17: 527-540. 10.1016/j.devcel.2009.09.005.CrossRefPubMedPubMedCentral
39.
Gélinas C, White E: BH3-only proteins in control: specificity regulates MCL-1 and BAK-mediated apoptosis. Genes Dev. 2005, 19: 1263-1268.CrossRefPubMed
40.
Opferman JT, Iwasaki H, Ong CC, Suh H, Mizuno S, Akashi K, Korsmeyer SJ: Obligate Role of Anti-Apoptotic MCL-1 in the Survival of Hematopoietic Stem Cells. Science. 2005, 307: 1101-1104. 10.1126/science.1106114.CrossRefPubMed
41.
Motoyama N, Wang F, Roth KA, Sawa H, Nakayama K, Nakayama K, Negishi I, Senju S, Zhang Q, Fujii S, Loh DY: Massive cell death of immature hematopoietic cells and neurons in Bcl-x-deficient mice. Science. 1995, 267: 1506-1510. 10.1126/science.7878471.CrossRefPubMed
42.
Wagner KU, Claudio E, Rucker EB, Riedlinger G, Broussard C, Schwartzberg PL, Siebenlist U, Hennighausen L: Conditional deletion of the Bcl-x gene from erythroid cells results in hemolytic anemia and profound splenomegaly. Development. 2000, 127: 4949-4958.PubMed
43.
Richmond TD, Chohan M, Barber DL: Turning cells red: signal transduction mediated by erythropoietin. Trends Cell Biol. 2005, 15: 146-155. 10.1016/j.tcb.2005.01.007.CrossRefPubMed
44.
Quelle FW, Wang J, Feng J, Wang D, Cleveland JL, Ihle JN, Zambetti GP: Cytokine rescue of p53-dependent apoptosis and cell cycle arrest is mediated by distinct Jak kinase signaling pathways. Genes Dev. 1998, 12: 1099-1107. 10.1101/gad.12.8.1099.CrossRefPubMedPubMedCentral
45.
Puthier D, Bataille R, Amiot M: IL-6 up-regulates Mcl-1 in human myeloma cells through JAK/STAT rather than Ras/MAP kinase pathway. Eur J Immunol. 1999, 29: 3945-3950. 10.1002/(SICI)1521-4141(199912)29:12<3945::AID-IMMU3945>3.0.CO;2-O.CrossRefPubMed
46.
Kuribara R, Honda H, Matsui H, Shinjyo T, Inukai T, Sugita K, Nakazawa S, Hirai H, Ozawa K, Inaba T: Roles of Bim in Apoptosis of Normal and Bcr-Abl-Expressing Hematopoietic Progenitors. Mol Cell Biol. 2004, 24: 6172-6183. 10.1128/MCB.24.14.6172-6183.2004.CrossRefPubMedPubMedCentral
47.
Aichberger KJ, Mayerhofer M, Krauth M-T, Vales A, Kondo R, Derdak S, Pickl WF, Selzer E, Deininger M, Druker BJ, et al: Low-Level Expression of Proapoptotic Bcl-2-Interacting Mediator in Leukemic Cells in Patients with Chronic Myeloid Leukemia: Role of BCR/ABL, Characterization of Underlying Signaling Pathways, and Reexpression by Novel Pharmacologic Compounds. Cancer Res. 2005, 65: 9436-9444. 10.1158/0008-5472.CAN-05-0972.CrossRefPubMed
48.
Kuroda J, Puthalakath H, Cragg MS, Kelly PN, Bouillet P, Huang DCS, Kimura S, Ottmann OG, Druker BJ, Villunger A, et al: Bim and Bad mediate imatinib-induced killing of Bcr/Abl+ leukemic cells, and resistance due to their loss is overcome by a BH3 mimetic. Proc Natl Acad Sci USA. 2006, 103: 14907-14912. 10.1073/pnas.0606176103.CrossRefPubMedPubMedCentral
49.
Nordigarden A, Kraft M, Eliasson P, Labi V, Lam EWF, Villunger A, Jonsson J-I: BH3-only protein Bim more critical than Puma in tyrosine kinase inhibitor-induced apoptosis of human leukemic cells and transduced hematopoietic progenitors carrying oncogenic FLT3. Blood. 2009, 113: 2302-2311. 10.1182/blood-2008-07-167023.CrossRefPubMed
50.
Dai Y, Grant S: Targeting Multiple Arms of the Apoptotic Regulatory Machinery. Cancer Res. 2007, 67: 2908-2911. 10.1158/0008-5472.CAN-07-0082.CrossRefPubMed
51.
Opferman JT, Letai A, Beard C, Sorcinelli MD, Ong CC, Korsmeyer SJ: Development and maintenance of B and T lymphocytes requires antiapoptotic MCL-1. Nature. 2003, 426: 671-676. 10.1038/nature02067.CrossRefPubMed
52.
James C, Ugo V, Le Couedic J-P, Staerk J, Delhommeau F, Lacout C, Garcon L, Raslova H, Berger R, Bennaceur-Griscelli A, et al: A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera. Nature. 2005, 434: 1144-1148. 10.1038/nature03546.CrossRefPubMed
53.
Wernig G, Kharas MG, Okabe R, Moore SA, Leeman DS, Cullen DE, Gozo M, McDowell EP, Levine RL, Doukas J, et al: Efficacy of TG101348, a Selective JAK2 Inhibitor, in Treatment of a Murine Model of JAK2V617F-Induced Polycythemia Vera. Cancer Cell. 2008, 13: 311-320. 10.1016/j.ccr.2008.02.009.CrossRefPubMed
54.
Pikman Y, Lee BH, Mercher T, McDowell E, Ebert BL, Gozo M, Cuker A, Wernig G, Moore S, Galinsky I, et al: MPLW515L Is a Novel Somatic Activating Mutation in Myelofibrosis with Myeloid Metaplasia. PLoS Med. 2006, 3: e270-10.1371/journal.pmed.0030270.CrossRefPubMedPubMedCentral
55.
Verstovsek S: Therapeutic Potential of Janus-activated Kinase-2 Inhibitors for the Management of Myelofibrosis. Clin Cancer Res. 2010, 16: 1988-1996. 10.1158/1078-0432.CCR-09-2836.CrossRefPubMed
56.
Lessene G, Czabotar PE, Colman PM: BCL-2 family antagonists for cancer therapy. Nat Rev Drug Discov. 2008, 7: 989-1000. 10.1038/nrd2658.CrossRefPubMed
Metadata
Title
Bim and Mcl-1 exert key roles in regulating JAK2V617Fcell survival
Authors
Joëlle Rubert
Zhiyan Qian
Rita Andraos
Daniel A Guthy
Thomas Radimerski
Publication date
01-12-2011
Publisher
BioMed Central
Published in
BMC Cancer / Issue 1/2011
Electronic ISSN: 1471-2407
DOI
https://doi.org/10.1186/1471-2407-11-24

Other articles of this Issue 1/2011

BMC Cancer 1/2011 Go to the issue

Research article

Effects of EpCAM overexpression on human breast cancer cell lines

Research article

P53 in human melanoma fails to regulate target genes associated with apoptosis and the cell cycle and may contribute to proliferation

Study protocol

The use of erlotinib in daily practice: a study on adherence and patients' experiences

Research article

MicroRNA-203 inhibits cell proliferation by repressing ΔNp63 expression in human esophageal squamous cell carcinoma

Research article

HNF1α inhibition triggers epithelial-mesenchymal transition in human liver cancer cell lines

Research article

Genes Associated With Prognosis After Surgery For Malignant Pleural Mesothelioma Promote Tumor Cell Survival In Vitro
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits